Immuno-Oncology | Specialty

Dr. Brody on Addressing Acquired Resistance to Immunotherapy in Non-Hodgkin Lymphoma

May 28th 2020

Joshua Brody, MD, discusses addressing required resistance to immunotherapy in non-Hodgkin lymphoma.

Dr. Otterson on the Utility of Immunotherapy in NSCLC

May 28th 2020

Gregory A. Otterson, MD, discusses data examining immunotherapy alone versus in combination in non–small cell lung cancer.

FDA Approves Nivolumab/Ipilimumab Plus Chemo for Frontline NSCLC

May 27th 2020

The FDA has approved nivolumab combined with ipilimumab and chemotherapy for use as a frontline treatment for patients with metastatic or recurrent non–small cell lung cancer.

Lopes Describes Approach for Discontinuing Immunotherapy in Metastatic Lung Cancer

May 27th 2020

Gilberto de Lima Lopes, MD, discusses the appropriate duration of immunotherapy in lung cancer, treatment-related adverse events, and remaining challenges faced in the space.

NICE Recommends Atezolizumab Combo in Frontline TNBC

May 23rd 2020

The UK's National Institute for Health and Care Excellence has recommended the combination of atezolizumab and nab-paclitaxel as a treatment for patients with unresectable, locally advanced, or metastatic triple-negative breast cancer whose tumors express PD-L1 at a level of 1% or more and have not had prior chemotherapy for metastatic disease.

Durvalumab/Olaparib Regimen Reveals Promising pCR Probability Across High-Risk HER2- Breast Cancer

May 23rd 2020

Lajos Pusztai, MD, DPhil, discusses the results from the I-SPY 2 trial, as well as the clinical implications of the findings.

Dr. Sznol on the Use of Immunotherapy in Melanoma

May 22nd 2020

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

Immunotherapy Revolutionizes Melanoma Treatment Paradigm

May 21st 2020

Mario Sznol, MD, discusses the current immunotherapy paradigm in melanoma and promising agents that are in development.

Immunotherapy Revolutionizes Melanoma Treatment Paradigm

May 21st 2020

Mario Sznol, MD, discusses the current immunotherapy paradigm in melanoma and promising agents that are in development.

Dr. Voorhees on the Benefit of Monoclonal Antibodies in Myeloma

May 20th 2020

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Dr. Bazhenova on the PACIFIC Trial With Durvalumab in NSCLC

May 20th 2020

Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.

Immunotherapy-Based Triplet Highly Active in Frontline HER2+ Esophagogastric Cancer

May 19th 2020

Pembrolizumab combined with trastuzumab and chemotherapy demonstrated promising clinical activity in patients with HER2-positive metastatic esophagogastric cancer.

Dr. Bazhenova on the PACIFIC Trial With Durvalumab in NSCLC

May 19th 2020

Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.

Chaft Crafts Considerations for Restarting Immunotherapy in Lung Cancer

May 19th 2020

Jamie E. Chaft, MD, provides insight into IRAEs and immunotherapy restart, considerations for immunotherapy in the pre- and post-operative period, outlines biomarker research in lung cancer, and projects her hopes for the future use of this approach in this space.

Dr. Carbone on the Impact of Immunotherapy in Lung Cancer

May 19th 2020

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

Dr. Rugo on Recent Updates With Immunotherapy in TNBC

May 19th 2020

Hope S. Rugo, MD, discusses recent updates with immunotherapy in triple negative breast cancer.

Dr. Savvides on the Utility of Immunotherapy in Lung Cancer

May 19th 2020

Panayiotis S. Savvides, MD, discusses the utility of immunotherapy in lung cancer.

Dr. Carbone on the Impact of Immunotherapy in Lung Cancer

May 19th 2020

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

Dr. Rugo on Recent Updates With Immunotherapy in TNBC

May 19th 2020

Hope S. Rugo, MD, discusses recent updates with immunotherapy in triple negative breast cancer.

FDA Approves Nivolumab/Ipilimumab for Frontline Advanced PD-L1+ NSCLC

May 15th 2020

The FDA has approved the combination of nivolumab and ipilimumab for the first-line treatment of patients with PD-L1–positive metastatic or recurrent non–small cell lung cancer that does not have EGFR or ALK genomic tumor aberrations.